CTIS2023-506971-89-00招募中1 期
A Phase III Prospective, Multicenter, Open-label Study to Assess Diagnostic Efficacy of a Novel 18F-labelled Tracer, SYN2, for Positron Emission Tomography in Subjects with Suspected Coronary Artery Disease - SAFER3
Synektik S.A.0 个研究点目标入组 170 人开始时间: 2023年8月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Provision of signed and dated informed consent form., Stated willingness to comply with all study procedures and availability for the duration of the study., Male or female, aged over 18 years of age., At the time of enrolment, the subject has been scheduled via written documentation to undergo an invasive coronary angiography for the assessment of CAD., Must be capable of undergoing the pharmacological or exercise stress imaging protocols., For females of reproductive potential: use of sufficiently effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional one week after the last IMP administration. A sufficient contraceptive method includes mechanical barrier (e.g., a male condom or a female diaphragm), combined [estrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation [oral, intravaginal, transdermal], progestogen-only hormonal anticonception associated with inhibition of ovulation [oral, injectable, implantable], IUD or IUS. Sexual abstinence is allowed when this is the preferred and usual lifestyle of the subject., For males of reproductive potential: use of condoms or other methods to ensure effective contraception with a partner for 3 months after last IMP exposure., Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout the study duration.
排除标准
- •Subjects who have an established diagnosis of CAD as confirmed by any of the following: a. Previous myocardial infarction (MI); b. Previous coronary revascularization, such as percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)., Known allergy or hypersensitivity for SYN2 components and other acridine derivatives such as Aminacrine, Ethacridine and Euflavine., Subjects incapable of undergoing pharmacological or exercise cardiac stress testing., Subjects who are unable to undergo all the imaging procedures or who have a current illness or pathology that, in the opinion of the investigator, would pose a significant safety risk for the subject or for whom the participation may compromise the management of other diseases or the investigator judges to be unsuitable for participation in the study., Documented history of heart failure and/or cardiomyopathy and/or prior LV ejection fraction (LVEF) <40%)., Subjects with severe valvular disease (Stages C, D defined by 2020 ACC/AHA Guideline)., Subjects scheduled for or planning to undergo any cardiac interventional procedures between enrolment and ICA (e.g., balloon angioplasty or bypass surgery)., Subjects undergoing evaluation for heart transplantation or with a history of heart transplantation., Subjects enrolled in another clinical study within the 30 days prior to being enrolled in this study or scheduled to participate in another clinical study during the 7-day follow-up period of this study (excepting post-marketing observational clinical studies)., Female subjects who are pregnant, have a positive (+) pregnancy test, or the possibility of pregnancy cannot be ruled out prior to dosing, or the subject is breastfeeding. The females of childbearing potential must have a negative serum pregnancy test at screening and serum/urine pregnancy test within 4 hours prior to the imaging]
研究者
相似试验
进行中（未招募）
不适用
A Prospective, Multicenter, Open-label, Phase 3b Study of Human Plasma-Derived Factor XIII Concentrate in Subjects with Congenital Factor XIII DeficiencyEstudio prospectivo, multicéntrico, con etiqueta abierta, en fase 3b, del concentrado de factor XIII derivado del plasma humano en sujetos con deficiencia congénita de factor XIIICongenital Factor XIII deficiencyDeficiencia congénita de factor XIIIMedDRA version: 9.1Level: LLTClassification code 10016083Term: Factor XIII deficiencyEUCTR2009-010722-19-ESCSL Behring LLC40
进行中（未招募）
1 期
Study, in which all know the treatment assigned to the patient, conducted in more sites, to evaluate the efficaty, safety, and metabolism of Kedrion in venous Human Normal Immunoglobulin (IVIg) 10% in child with Primary Immunodeficiency Disease (PID)Pediatric Patients Affected by Primary Immunodeficiency Disease.MedDRA version: 20.0Level: PTClassification code 10064859Term: Primary immunodeficiency syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-001496-32-SKKEDRION S.P.A30
进行中（未招募）
1 期
Study, in which all know the treatment assigned to the patient, conducted in more sites, to evaluate the efficaty, safety, and metabolism of Kedrion in venous Human Normal Immunoglobulin (IVIg) 10% in child with Primary Immunodeficiency Disease (PID)Pediatric Patients Affected by Primary Immunodeficiency DiseaseMedDRA version: 20.0Level: PTClassification code 10064859Term: Primary immunodeficiency syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-001496-32-ITKEDRION S.P.A30
进行中（未招募）
1 期
Study, in which all know the treatment assigned to the patient, conducted in more sites, to evaluate the efficaty, safety, and metabolism of Kedrion in venous Human Normal Immunoglobulin (IVIg) 10% in child with Primary Immunodeficiency Disease (PID)Pediatric Patients Affected by Primary Immunodeficiency Disease.MedDRA version: 20.0Level: PTClassification code 10064859Term: Primary immunodeficiency syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-001496-32-HUKEDRION S.P.A30
进行中（未招募）
1 期
Study, in which all know the treatment assigned to the patient, conducted in more sites, to evaluate the efficaty, safety, and metabolism of Kedrion in venous Human Normal Immunoglobulin (IVIg) 10% in child with Primary Immunodeficiency Disease (PID)EUCTR2020-001496-32-PTKEDRION S.P.A30